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CHAPTER І^  
INTRODUCTION AND AIM OF THE STUDY 
1.1. Introduction 
Since the beginning of this century the activity of substances such as 
medicinal drugs or hormons has been explained mainly by the interaction 
of such substances with a "receptive substance" (usually described simply 
as receptor) which is localized on or in the receptor cell (Langley, 
1905). Depending on the affinity of the substance for the receptor a 
coupling is established, whereupon biological effects are or are not 
produced according to the intrinsic activity of the substance. In 1948 
Ahlquist described the various effects of six sympathico-mimetics on 
organs and tissues and, on the basis of their different potencies, 
concluded that there must be two types of adrenergic receptors : a-
receptors and 3-receptors. Stimulation of α-receptors generally results 
in constriction of smooth muscle tissues, whereas stimulation of S-
receptors mainly causes dilation. The relative affinity of some sympathico-
mimetics for the α-receptors can be written as: phenylephrine > noradre­
naline > adrenaline » isoprenaline (Ahlquist, 1940). In an analogous way 
Lands et al. in 1967 introduced a functional division of the ß-receptors 
irto two subtypes. Various 3-sympathico-mimetics showed different effects 
on organs and tissues such as the heart, the bronchi and blood vessels, 
and in view of this Lands et al. postulated that the heart contained 
3.-receptors while the airways and blood vessels in skeletal muscles 
contained ß.-receptors. The relative affinity for the 3.-receptor can 
be written as: noradrenaline > isoprenaline > adrenaline » phenylephrine; 
and that for the B.-receptor as: adrenaline > isoprenaline > noradrena-
line »phenylephrine (Lands et al., 1967). The distribution of a- and 3-
receptors in various organs and the response to stimulation are shown in 
Table I. 
In 1976 Ariëns and Simonis introduced a more physiological division of 
3-receptors into two subtypes. Adrenaline, a hormon from the adrenal 
medulla, was thought to act via 3„-receptors, while the sympathetic 
H 
neurotransmitter noradrenaline acted via 3_-receptors. This division 
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into Í5 - and ß -receptors to some extent parallels that into β - and 0 -
receptors. 
Organ 
Heart 
Blood vessels in skeletal 
muscle and coronary vessels 
Blood vessels in 
kidney 
Bronchi 
Intestinal wall 
skin 
Intestinal sphincters 
Uterus 
Kidney 
Skeletal muscle 
Adipose tissue 
Pancreas 
and 
* In brackets, the receptor 
concentration. 
Receptor 
type 
ßl 
0 2 
α 
α 
β
? 
(ß2)* 
<v 
( 0 . ) 
α and 0 
a. 
α 
ß1 
к 
*ι 
α 
β
2 
type 
(ß 2 ) 
( 0 2 ) 
(^) 
Response 
increase in heart rate 
increase in contractility 
increase in conduction 
increase in excitability 
vasodilation 
vasoconstriction 
vasoconstriction 
relaxation 
relaxation 
constriction 
increase in contractility 
decrease in contractility 
renin release 
tremor 
glycogen©lysιs 
lipolysis 
inhibition of insulin release 
stimulation of insulin release 
occurring in a relatively lower 
Table I Distribution of adrenergic receptors in some organs and 
response to stimulation 
It has meanwhile been found that the α-receptors can likewise be divided 
into ttj- and a2-receptors (Wikberg, 197Θ). It was thought that α -recep­
tors are localized postsynaptically in the sympathetic synapse, while 
OU-receptors presynaptically exert an inhibitory influence on the release 
of the neurotransmitter noradrenaline. A functional significance of the 
division into a.- and ou-receptors in the treatment of patients remains 
to be established (Djurup, 1981). 
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The division into 3 - and β -receptors, however, has proved to be of 
clinical importance in the treatment of patients. One of the first ß -
receptor blockers to be introduced - propranolol, which affects both 
β.- and 6 -receptors - proved to cause severe bronchial obstruction in 
asthmatic patients (McNeill, 1964; Zacharias et al., 1972). This was 
explained by the blocking effect of propranolol on the β-receptors in 
the airways. Although propranolol is of great clinical importance in 
the treatment of cardiovascular diseases, its use in asthmatic patients 
is contraindicated in view of this side effect. From this point of view 
the development of ß -selective blockers such as metoprolol and atenolol 
seemed a distinct advance. However, m asthmatic patients β -selective 
blockers could also exert an unfavourable influence on lung function, but 
this was far less marked than that of the non-selective ß-blockers 
(Johnsson et al. , 1975; Vilsvik and Schaanning, 1976). Various ß-adreno-
ceptor antagonists are listed in Table II. 
Drug 
Acebutolol 
Alprenolol 
Atenolol 
Metoprolol 
Oxprenolol 
Pindolol 
Practocol 
Propranolol 
Sotalol 
Timolol 
β
Γ 
ßl 
ßl 
ßl 
ßl 
ßl 
ßl 
ßl 
ßl 
ßl 
ßl 
-sei 
> 
+ 
» 
» 
+ 
+ 
» 
+ 
+ 
+ 
ectivity 
ß2 
ß2 
ß2 
ß2 
ß2 
ß2 
ß2 
ß2 
ß2 
ß2 
ISA 
+ 
+ 
-
-
+ + 
+++ 
+ + 
-
-
— 
ßl + ßa a non-selective compound; 
ßl >s ßa, ßi selectivity 
Table II Various ß-adrenoceptor blocking agents 
and their differentiation with respect to 
ßi selectivity, and intrinsic sympatho-
mimetic activity (ISA) 
Similar observations were made on the ß-receptor stimulators used m 
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the treatment of asthmatic symptoms. Non-selective ß-receptor stimula-
tors such as isoprenalme and orciprenaline caused unmistakable broncho-
dilation in asthmatic patients, but in addition had a marked effect on 
the cardiovascular system: they increased the heart rate. These tachy-
cardias were ascribed to the stimulant action on the 0 -receptors of 
the heart. In in-vitro studies β -selective receptor stimulators had 
virtually no effect on the heart (Persson and Johnsson, 1970; Broadley 
and Nicholson, 1979) but, dependent on mode of administration and 
dosage, cardiac side effects were nevertheless observed in patients 
(Thinnger and Svedmyr, 1976; Larsson and Svedmyr, 1977). In view of 
these findings supplementary studies were performed which demonstrated 
that the division into organs with &.- and with β -receptors postulated 
by Lands et al. (1967) was too rigid. Functional studies with selective 
stimulators and blockers in cats revealed that the heart contained β -
as well as β -receptors and the airways β - as well as β -receptors, 
which induced a similar response to stimulation (Carlsson et al., 1972; 
Lulich et al., 1976). These research results were subsequently confirmed 
by ß-receptor binding studies which revealed that, in the airways as 
well as in the heart, 10-30% of the ß-receptor population were of the 
β -subtype or the β -subtype, respectively (Barnett et al., 1979; 
Hedberg, 1980). Since organs contain a mixed ß-receptor population, 
methods used to measure the selectivity of ß-adrengeric stimulators or 
blockers in functional studies in patients should differ from those used 
as a rule so far. After all, under basal conditions the effects of a 
ß-adrenergic substance on an organ can be caused by its influence on 
both ß-receptor subtypes. The selectivity of, say, a ß-receptor blocker 
in the airways can therefore be determined only by establishing the 
extent to which this blocker blocks the effect of a β -selective stim­
ulator on the airways. 
1.2. Aim of the study 
Since ß-receptor blockers are frequently used in the treatment of 
patients with cardiovascular diseases, it is important to establish 
the extent to which β.-selective blockers can be used also in patients 
with concomitant obstructive lung disease. Three β.-selective blockers 
are at present available for use in medical practice: acebutolol, aten-
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olol and metoprolol. The first aim of the study was to compare the 
ventilatory effects of these three agents in asthmatic patients, in 
whom the degree of 3 -selectivity was studied by administering the ß--
selective agonist terbutaline by inhalation (see Chapter IV). The find-
ings obtained prompted an extension of the study in two different ways. 
The improvement in ventilation after terbutaline stimulation during 
placebo, atenolol and metoprolol was the same - a finding consistent 
with the 3.-selective character of these agents. The response to ter-
butaline during acebutolol medication was less pronounced, possibly 
indicating lower degree of 3.-selectivity. In the next group of asthmatic 
patients the ventilatory response to increasing doses of intravenously 
given terbutaline was therefore studied during medication with placebo, 
metoprolol and acebutolol (Chapter V). 
Since the three 3,-selective agents all proved to cause a slight in-
crease in bronchospasm in asthmatic patients, the question was consid-
ered whether the presence of 3 -receptors in the airways might explain 
this, partly also in view of the sometimes marked adverse reaction to 
3.-selective blockers which these patients may show (Tattersfleid, 1981, 
Jackson, 1981; Skinner, 1981). To verify this, the effect of the 3 -
selective agonist prenalterol on ventilation in asthmatics was studied 
(Chapter VI). For this purpose the dose-effect curve in a group of 
asthmatics was established in terms of haemodynamic and ventilatory 
parameters during terbutaline and prenalterol medication. Comparison 
of the haemodynamic effects of terbutaline and prenalterol, it was 
assumed, might make it possible also to explain the cardiac side effects 
of the З.-selective agonists. 
Many studies on the ventilatory effects of 3-receptor blockers have 
been published. The results have varied, possibly as a result of dif­
ferences in the patient populations studied. The next chapter will 
therefore first discuss the pathophysiological mechanisms involved in 
the pathogenesis of bronchial constriction in CNSLD ( = chronic non­
specific lung disease = chronic obstructive lung disease = COLD) 
(Chapter II). Chapter III will then discuss the criteria to be ful-
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filled by CNSLD patients for clinical pharmacological research with 
ß-adrenergic substances. 
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CHAPTER II 
THE CNSLD SYNDROME 
2.1. Introduction 
Patiens suffering from CNSLD may show symptoms of periodical or continuous 
dyspnoea and/or chronic or recurrent cough, sometimes with expectoration. 
Depending on the predominant symptoms the condition of these patients may 
be described with a clinical diagnosis such as bronchial asthma, asthmatic 
bronchitis, chronic obstructive bronchitis or emphysema. Unequivocal 
differentiation of these clinical pictures is not always possible, and 
this can lead to great conceptual confusion. 
Fletcher et al. (1964) clearly demonstrated this by having a group of 
patients examined by American and by British physicians. The former 
characterized the patients as suffering from emphysema, while the latter 
described them as chronic bronchitis patients. 
Since patients may show various disease symptoms and transitions of 
clinical picture in the course of life, these affections are often 
regarded as different manifestations of the same syndrome, in which the 
same underlying pathophysiological mechanisms play a role. O n e et al. 
therefore proposed that these patients be defined as suffering from 
chronic non-specific lung disease (CNSLD) (One et al., 1961). Also 
other general descriptive terms are used, such as chronic obstructive 
lung disease (COLD), chronic obstructive respiratory disease (CORD) and 
in Dutch chronische aspecifieke respiratoire aandoeningen (CARA) . 
Bronchial obstruction is a frequent functional characteristic of these 
patients. It often results from an interaction between exogenous and 
endogenous factors. Important endogenous factors are bronchial hyper-
reactivity and an allergic constitution. Other endogenous factors may 
be ciliary dysfunction, with disturbed mucociliary transport (Eliasson 
et al., 1977), and metabolic disorders such as a^-antitrypsin deficiency 
with possible destruction of pulmonary tissue resulting in loss of 
alveolar elasticity, and consequently bronchial obstruction during the 
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expiratory phase (Morse, 1978). Exogenous factors include the numerous 
irritants which enter the airways, be it in the form of allergens or 
as non-specific irritants such as temperature changes or air pollution. 
Respiratory infections can also play an important role in the patho-
genesis of airway obstruction. 
2.2. Bronchial hyperreactivity 
Bronchial hyperreactivity can be defined as an abnormal sensitivity of 
the airways to a series of physical, chemical or pharmacological stimuli 
which, if administered to normal test subjects in the given concentration, 
have no bronchoconstnctor effect (De Vries et al., 1962) . Bronchial 
hyperreactivity shows intenndividual differences and a diurnal rhythm 
(De Vries et al., 1962), and it can vary in the course of time in res-
ponse to, for example, viral respiratory infections (Empey et al., 1976) 
or due to inhalation of irritants such as ozone (Holtzman et al., 1979). 
The autonomic nervous system plays an important role as regulator of the 
reactivity of the bronchial tree. There is an extensive parasympathetic 
innervation of the airways by efferent and afferent vagus nerve fibres. 
These nerve fibres show increased activity after stimulation of "irritant" 
receptors in the airways by non-specific irritants, antigens and mediators 
released in antigen-antibody reactions. 
The sympathetic innervation of the airways is considerably less extensive 
than the parasympathetic innervation. In the larger airways sympathetic 
nerve fibres have been histologically demonstrated only along the blood 
vessels (O'Donnell and Saar, 1973). However, adrenergic receptors are 
present throughout the bronchial tree. Stimulation of the ß-adrenergic 
receptors in the airways (mostly of the β.-subtype) has a bronchodilator 
effect based on relaxation of the smooth muscle cells and increased 
ciliary activity of the ciliated mucosal epithelial cells (Foster et al., 
1976). Stimulation of the ß-reeeptors on the mast cells causes stabilization 
of the cell membranes of these cells (Gold, 1979). Mast cells are localized 
in the mucosa and submucosa and on the mucous membrane in the lumen of 
the airways (Patterson et al., 1974; Guerzon et al., 1979). It is assumed 
that the tone of the airways is determined by the balance between para-
sympathetic and sympathetic activity. Thus a parasympathetically mediated 
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bronchoconstriction can be relieved by sympathico-adrenergic stimulation, 
and vice versa. Predominance of the parasympathetic system (Yu et al., 
1972; Nadel, 1977) or blockade of the ß-adrenergic sympathetic system 
(Szentivanyi, 1968; Reed, 1968) might be responsible for bronchial 
hyperreactivity. For determination of the degree of bronchial hyper-
reactivity in CNSLD patients we refer to the literature (Gokemeyer, 1976; 
Pauwels and Van der Straeten, 1982). 
2.3. Allergic constitution 
Some 20-40% of CNSLD patients have an allergic constitution as well as a 
hyperreactivity. These patients are congemtally predisposed to excessive 
production of IgE antibodies in response to allergen exposure. In some 
patients excessive production of the antibody of an laG subclass is ob-
served as well (Davies and Pepys, 1976). Allergens known to play a role 
in CNSLD patients are among others- house dust, pollen, animal epithelium 
and fungi, against which a specific IgE can be produced. The cause of 
the excessive immunoglobulin production has so far remained obscure. The 
IgE produced has cytophilic properties and attaches itself to the cell 
membrane of the mast cells and basophil granulocytes. IgG. also has cyto-
philic properties but its attachment to the cell membrane of the mast 
cell is of much shorter duration (Davies and Pepys, 1976). Upon renewed 
allergen inhalations this allergen attaches itself to two immunoglobulin 
molecules of the mast cell, which leads to activation of the mast cell 
and release of mediators stored in the granules. The granules of the 
mast cell contain several "preformed mediators", some of which have a 
direct constrictor effect on the smooth muscle fibres in the airways, 
e.g. histamine and serotonin. A survey of the substances contained in 
the granules of the mast cells and their functions is given in Table I. 
As a result of allergen exposure the sensitized mast cell also starts to 
produce several other mediators, largely from arachidonic acid which is 
released from the phospholipids of the mast cell membrane after activation 
of phospholipase A2. A survey of these "membrane-derived" mediators and 
their functions is given in Table II. 
The mediators released after activation of the mast cell therefore have 
several properties, of which the following three are the most important: 
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- spasm of the smooth bronchial musculature 
- vaso-activity in the sense of vasodilation and increased capillary 
permeability 
- chemotactic properties 
Mediator 
Histamine 
Sprotomn 
Eosinophil 
factor of 
Neutrophil 
factor 
Heparin 
Chymase 
chemotactic 
anaphylaxis 
chemotactic 
Arylsulphatase A 
N-acetyl-beta-D-
glucosamin idase 
Chondroitin 4 and 6 sulphate 
Functions 
-
-
-
-
-
-
-
-
-
contraction of smooth muscles 
increased vascular permeability 
increased level of cyclic AMP 
chemokinesis 
contraction of smooth muscles 
increased vascular permeability 
chemotactic attraction and deactiva-
tion of eosinophils and neutrophils 
chemotactic attraction and deactiva-
tion of neutrophils 
anticoagulation 
anti-thrombin III interaction 
inhibition of complement activation 
proteolysis 
hydrolysis of SRS-A and other 
sulphate esters 
cleavage of glucosamine residues 
platelet factor IV interaction 
Table 1^  Mediators preformed in mast cell granules and their functions 
2.4. Bronchial obstruction 
The bronchial obstruction which occurs in response to hyperreactivity 
and allergen provocation, is caused by morphological changes in the 
airways which may result from: 
- spasm of the smooth bronchial musculature which can be caused by 
a shift in the balance between the parasympathetic and the sympathetic 
system or by a direct influence of mediators; 
- vaso-activity of the mediators, which can give rise to oedema of the 
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mucosa and submucosa of the bronchial wall, resulting in narrowing of 
the bronchial lumen; 
chemotactic activity of the mediators, which can give rise to a 
cellular infiltrate in the bronchial wall, likewise resulting in 
narrowing of the bronchial lumen; 
predominance of parasympathetic activity in the bronchial tree via 
stimulation of the irritant receptors, be it directly or indirectly 
via the mediators released from the mast cells, which in addition 
causes an increase in bronchial mucus secretion with subsequent 
accumulation of secretion in the lumen resulting in obstuction. 
Mediator Functions 
Slow-reacting substance of - contraction of bronchioles 
anaphylaxis (SRS-A) - increased vascular permeability 
Platelet-activating factors - platelet aggregation 
- serotonin release 
Lipid chemotactic factors - chemotactic attraction of neutro-
phils and eosinophils 
- chemokinesis of neutrophils 
- deactivation of neutrophils 
Prostaglandines - bronchoconstnction 
- many other functions 
Table II Mast cell membrane-derived mediators and their functions 
These changes are usually reversible, either spontaneously or in 
response to medication, and constitute the asthmatic component of the 
CNSLD syndrome. More persistent conditions may be associated with 
other changes, e.g. hypertrophy of the bronchial mucus glands and 
muscular layer and formation of fibrous tissue in the bronchial wall, 
leading to bronchial obstruction. Diminished alveolar elasticity or 
destruction of the alveoli - the supporting skeleton of the bronchioles 
can cause these smaller airways to collapse during the expiration. The 
presence of the lastmcntioned changes indicates a chronic, usually 
irreversible situation, as is to be expected, m chronic obstructive 
bronchitis and/or emphysema. 
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2.5. Conclusions 
The CNSLD syndrome thus entails a complex of factors which can load to 
bronchial obstruction. Since these factors are so numerous the clinical 
pictures are more variable than can be defined with clinical diagnosis 
such as bronchial asthma, asthmatic bronchitis etc.. Consequently the 
method of selecting patients for clinical pharmacological studies on 
the effect of 3-adrenergic aaents on pulmonary function under the 
diagnosis CNSLD or via a clinical diagnosis must be regarded as in­
accurate (McDevitt, 1978; Greefhorst and Van Herwaarden, 1982). 
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CHAPTER III 
EFFECTS OF BETA-BLOCKADE IN RELATION TO THE CHARACTERISTICS OF PATIENTS 
WITH CNSLD. 
3.1. Introduction 
The ventilatory effects of S-blockade have been the subject of a con-
siderable amount of research. Results have not infrequentli been con-
troversial. There is evidence that the differences in results are some-
times caused by differences in the patient populations studied (Perks 
et al., 1978; McDevitt, 1978). Since certain pathophysiological mechanisms 
in the airways play a role in CNSLD patients, it may be postulated that 
only data obtained in CNSLD patients are of importance. Not infrequently, 
unjustifiable conclusions are drawn from studies of the ventilatory 
effects of ß-blockers in test subjects without pulmonary symptoms (Kumana 
et al., 1974; Oh et al., 1978). 
As already mentioned a careful definition and characterization of CNSLD 
patients seems important for clinical pharmacological research; this can 
be achieved by registration of the following data: 
1. the duration and severity of the disease 
2. the degree of hyperreactivity of the bronchial tree 
3. the presence of allergic factors 
4. lung function, i.e. the degree of airway obstruction, its reversibility 
and the agent with which reversibility is obtained 
5. the degree of medication preceding the study 
6. the presence of complicating factors such as infections or allergen 
exposure, etc. 
The effects of 8-blockade in CNSLD patients will be discussed in relation 
to the abovementioned factors. 
3.2. Duration and severity of the disease 
Gayrard et al. (1971) studied the question whether a correlation existed 
between the severity of the disease and the ventilatory effects of pro-
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pranolol medication. The patients studied were arbitrarily devided into 
four groups on the basis of the severity of symptoms. The investigators 
established a significant correlation between the ventilatory effect of 
propranolol and the severity of symptoms. Despite this correlation the 
data were not predictive of an untoward effect of propranolol medication 
Some asthmatic patients with very mild symptoms likewise developed a 
severe reaction after propranolol medication. The ventilatory effect of 
3 -selective blockers in CNSLD patients is as a rule less marked than 
that of the non-selective blocker propranolol (Johnsson et al., 1975; 
Vislvik and Schaanning, 1976), but the selective agents, too, can cause 
unexpected large reactions (Skinner, 1981; Jackson, 1981; Tattersfield, 
1981). 
There are no indications that the duration of the disease influences 
the ventilatory response to 3-blockade (Gayrard et al., 1971; personal 
observations). 
3.3. Hyperreactivity 
The degree of bronchial hyperreactivity in CNSLD patients can be de-
termined with the aid of different tests. Widely used tests are the 
histamine or methacholine provocation test. Also exercise can be used 
to establish hyperreactivity by assessment of the degree of bronchial 
obstruction induced by an exercise test (Pauwels and Van der Straeten, 
1982). 
The degree of hyperreactivity established with the histamine provoca-
tion test showed no correlation with the ventilatory response to vari-
ous types of ß-blockers after oral administration (Gayrard et al., 1971; 
Ruffm et al., 1979; Ruffin et al., 1982; personal observations). It is 
therefore impossible to predict the ventilatory effect of a $-blocker on 
the basis of the degree of hyperreactivity. 
There are distinct indications that the non-selective blocker propra-
nolol enhances the degree of hyperreactivity (Dorow, 1982; Ruffin et 
al., 1982). Data in the literature show no agreement about the question 
whether a β -selective blocker likewise influences hyperreactivity. In 
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Dorow's study hyperreactivity (determined by histamine provocation) was 
found not to increase after ingestion of 50 mg metoprolol, but Ruffin 
observed an increase in hyperreactivity after ingestion of 100 mg meto-
prolol (Dorow, 1982; Ruffin et al., 1979). Pindolol, a non-selective 
ß-blocker with intrinsic sympathico-mimetic activity (ISA), did not 
influence the degree of hyperreactivity (Dorow, 1982,- Ruffin et al., 
1982). These investigators studied the hyperreactivity after a single 
oral doses of a ß-blocker. The effect of prolonged administration of 
these agents on hyperreactivity has not so far been studied. 
The degree of exercise-induced bronchoconstnction, which is also a 
parameter of hyperreactivity (Mellis et al. ,1979; Neyens, 1981), was 
found to increase after propranolol medication (Jones, 1972). Pindolol 
(the non-selective ß-blocker with ISA) and the β -selective blockers 
exerted no influence on the degree of exercise-induced bronchoconstnction 
(Greefhorst and Van Herwaarden, 1981; Lofdahl, 1982; Ruffin et al., 1982). 
3.4. Allergic constitution 
No correlation was found between the degree of bronchial obstruction 
which developes after administration of a selective or non-selective 
ß-blocker and the presence or absence of an allergic constitution 
(Gayrad et al., 1971; Benson et al., 1977; Von Wiehert et al., 1980; 
personal observations). 
3.5. Lung function 
There are no indications of a correlation between initial lung function 
and the degree of ventilatory response to ß-blockade in CNSLD patients 
(Gayrard et al., 1971; personal observations). 
With regard to the reversibility of a bronchial obstruction it can be 
stated that patients who respond to a ß-sympathico-mimetic with broncho-
dilation, as a rule show a decrease in lung function during ß-blockade. 
On the other hand, patients in whom a S-agonist cannot improve the 
bronchial obstruction (fixed or irreversible obstruction), as a rule 
show no deterioration of lung function during ß-blockade (Perks et al., 
1978; Chester et al., 1981; personal observations). An explanation is 
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to be sought in the fact that adrenergic substances act on the ß-receptors 
via which the tone of the smooth muscle fibres in the airways is influenced. 
With a view to the clinical diagnosis it can be assumed that an untoward 
effect of a S-blocker is to be expected in patients with reversible 
bronchial obstruction, e.g. with bronchial asthma and asthmatic bronchitis. 
Patients with the clinical picture of chronic bronchitis with an irreversible 
bronchial obstruction as a rule show no untoward response to ß-blockade. 
Caution, however, remains imperative because in these patients, too, an 
asthmatic component may be involved which may become manifest during 3-
blockade. 
In view of the fact that especially the ß2" r e c eP t o r s a r e important for 
bronchodilation, improvement of an airway obstruction by a ß^-selective 
agonist does not necessarily imply that a β -selective blocker might 
exert an untoward influence. On the basis of this consideration research 
has been devoted to the functional significance of the 3 - and 3,-
receptors separately in the airways of CNSLD patients. This is described 
in Chapter VI. 
3.6. Medication 
Medication prior to or during the study might influence the results ob­
tained. A point of primary importance in studying the effects on ob­
struction/dilation is that bronchodilator agents such as ß-sympatico-
mimetics, anticholinergic agents and xanthine derivations are discon-
tinued amply in advance. It has been established that these agents 
directly influence the tone of the bronchial muscle fibres (review Pater-
son, 1979). Since other anti-asthmatics such as cromoglycate and corti-
costeroids act via different mechanisms, e.g. stabilisation of mast cells 
and suppression of the inflammatory component, there are no arguments 
dictating discontinuation of these medications prior to a study with 3-
adrenergic substances (review Paterson, 1979). Especially the extent to 
which 3-sympathico-mimetics may influence the results should be established. 
It has been found that the density of 3-receptors on leucocytes and lung 
tissue can diminish in response to prolonged treatment with 3-agonists 
(Galant et al·., 197Θ, review Djurup, 1981). It has also been established 
that the metabolic response, e.g. production of cyclic AMP after 3-recep-
26 
tor stimulation, diminishes during prolonged treatment with ß-sympatico-
mimetics (Makino et al., 1977; Bruynzeel et al., 1979). Of importance is 
the extent to which this phenomenon of desensitization influences the 
ventilatory effects of ß-adrenergic substances during prolonged treatment 
of CNSLD patients. So far there have been no convincing indications that 
prolonged use of ß-stimulating agents in CNSLD patients reduce their 
response to administration of a ß-sympathico-mimetic (Larsson et al. , 
1976, review Djurup, 1981; Tashkm et al., 1902). For the purpose of our 
study it would therefore seem to be sufficient to discontinue treatment 
with ß-sympathico-mimetics and with other bronchodilator agents at least 
two days before the start of the study. 
3.7. Stability of the clinical picture 
Many CNSLD patients show a rather variable degree of bronchial obstruc-
tion due to variations in exogenous irritants and m bronchial hyper-
reactivity. Since studies with (3-receptor-active substances usually take 
a few days to weeks, it is important that the initial lung function 
parameters do not vary too widely during this period. It is therefore 
important to perform the study during periods devoid of marked variations 
in exogenous irritants and m bronchial hyperreactivity. With regard to 
the exogenous factors, variations in allergen exposure but also in non-
specific irritants have to be taken into account. 
Bronchial hyperreactivity can increase significantly particulary during 
and after bronchial infections, especially viral infections (Empey et al., 
1976). Research planning should account for these aspects. In this context 
it is also important that, during studies which cover a period of several 
days, lung function is measured at the same time of the day and preferably 
in the afternoon, when lung function remains stable over a number of hours 
(Connolly, 1979,- personal observations). In practical terms this means 
that studies are performed in patients whose initial lung function values 
vary by no more than 10% on the various days of the study; variations in 
excess of this might lead to erroneous conclusions (McDevitt, 1978; 
personal observations). 
27 
3.8. The ventilatory effects of the various 3-blockers 
The ventilatory effects of the various ß-blockers can be explained 
fairly simply with the aid of a balance model. The tone of the smooth 
musculature in the airways of an asthmatic patient results from the 
interaction of factors which promote bronchoconstriction and those which 
promote bronchodilation (Figure I). Dronchoconstriction can result from 
inhalation of irritants and allergens, via vagus nerve stimulation and/or 
release of mediators from the mast cells. Bronchodilation, on the other 
hand, can be promoted via stimulation of the broncial ß-receptors by 
circulating catecholamines and ß-sympathico-mimetics. If the two mechanisms 
are in balance, then the patient has no symptoms. 
bronchoconstriction bronchodilation 
BRONCHOCONSTRICTOR 
FORCES 
BRONCHODILATOR 
FORCES 
histamine 
serotonin 
cholineraic stimulation 
beta-blockers 
prostaglandins 
SRS-A and other mediators 
alpha-mimetics 
; 
V 
asthmatic 
complaints 
t 
/ \ 
endogenous cathecholamines 
Deta-mimetiLb 
theophyllines 
anti-cholinerglcs 
Indirectly actina broncho-
dilators 
alpha-receptor blockers 
/ 
N 
no asthmatic 
complaints 
Figure I 
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During an asthmatic attack the balance shifts in favour of constriction. 
In non-asthmatic persons the bronchodilation is predominant, and the 
abovementioned constriction-promoting factors are as a rule unable to 
cause bronchoconstriction. In patients without, but more especially in 
those with manifest asthmatic symptoms, ß-blockers can cause the balance 
to shift to constriction. 
The study of Benson et al., (1977) illustrates the ventilatory effects 
of the various (^-blockers. They studied 12 patients in a stable respiratory 
phase in whom at least 15% reversable bronchial obstruction had been 
demonstrated. On the test days these patients received, in a randomized 
double blind set-up, placebo, propranolol (100 mg), pindolol (5 mg) or 
atenolol (100 mg). Lung function was measured before and 2 hours after 
ingestion of the agent given. Next, isoprenaline was inhaled and lung 
function measured again. The results published by Benson et al. are 
graphically presented in Figure II. 
Chronic obstructive lungdiseose 
placebo propranolol pindolol 
ΔΡΕ^(Ι) (100 mg) (5 mg) 
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0.3 
0.2 
0.1 
о 
0.1 
0.2 
0 3 
CU 
0 5 
ν-, 
'Л 
ίΔ 
ΈΣΤ 
atenolol 
(100mg) 
I J 2 hrs post drug 
post isoprenaline 
Figure I I 
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Propranolol, the non-selective ß-Ыоскег without ISA, caused the most 
marked decrease in FEV.. The decrease in lung function during pindolol 
medication was decidedly less, indicating that a non-selective 3-blocker 
with ISA causes a less marked increase in constriction because the un­
favourable "weight" on the balance is limited. The 3.-selective blocker 
atenolol caused the same degree of increase in bronchoconstnction as 
pindolol. This means that 3 -selective blockers can also have an unfav­
ourable effect on lung function in asthmatics. After isoprenalme inha­
lation, lung function distinctly improved during placebo and atenolol 
medication, whereas the response to propranolol and pindolol was limited. 
These data are consistent with the fact that atenolol is a 3.-selective 
blocker. The B-sympathico-mimetic is therefore able to restore the balance 
via stimulation of the non-blocked β -receptors. During medication with 
a non-selective blocker the balance can again be restored by administration 
of a larger dose of a 3-sympathico-mimetic or of an agent such as theo­
phylline, which is a bronchodilator and does not act via 3-receptors. 
3.9. Conclusions 
The above considerations show that, in investigating the ventilatory 
effects of 3-blockers in CNSLD patients, only that type of study is of 
importance that is performed in CNSLD patients with a readily reversible 
bronchial obstruction in a stable phase of the disease, sufficiently 
long after discontinuing bronchodilator medication. Since even in such 
a group of patients the response to a 3-blocker can still vary consid­
erably, comparative studies of the effects of different 3-blockers in 
the same patient populations should be performed. Unjustifiable con­
clusions are still being drawn in some studies from results obtained 
in different groups of patients (Decalmer et al., 1978). 
In this context the reversibility of bronchial obstruction is best 
assessed by means of a stimulation test with a ß-sympathico-mimetic. 
Rumana et al. (1974) thougt that physical exercise induced adequate 
sympathetic stimulation, not only of the cardiovascular system but 
also of the airways. Meanwhile, however, various studies have demon-
strated that bronchodilation which occurs during physical exercise 
is not caused by stimulation of the bronchial 3-receptors but is pro-
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duced via a different mechanism (Van Herwaarden et al., 1979; Taylor 
et al., 1981; Greefhorst and Van Herwaarden, 1981). A stimulation test 
with a ß-sympathico-mimetic provides information, not only on the nature 
of a patient's lung disease but also on the reversibility of bronchial 
obstruction during ß-blockade; in this way it can be established whether 
the 3-blocker given is or is not 3.-selective. 
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Comparative Study of the Ventilatory Effects of Three Beta1-Selective 
Blocking Agents in Asthmatic Patients 
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Summary. A double blind pbeebo-controllcd Mudy 
of the ventilatory effects of three new bctai-sclec-
live adrenoceptor blockers was carried out in eight 
asthmatic patients Measurements were performed 
before and 2 3 and 4 h after ingestion of a single oral 
dose of placebo, atenolol 100 mg, metoprolol 100 mg 
or acebutolol 400 mg At each time ventilatory indi­
ces and heart rate were assessed before, during and 
15 mm after an exercise lest The ventilatory indices 
were re-assessed after challenge with terbutaline 
1 4 mg by inhalation The three beta-blocking agents 
caused equal falls in exercise heart rate two hours 
after ingestion, indicating the cquipotency of the car­
diac effects The three agents reduced significantly 
and to the same extent l-LV, and PEFR both before 
and after exercise The respiratory indices clearly 
improved after stimulation with terbutaline The 
response to terbutaline was less marked after 
acebutolol, which may indicate that it has a lower 
degree of betd^selectivity The beta-blockers did not 
show any influence on bronchodilalation during 
exercise, or on exercise-induced bronchospasm 
Key words: bcta^selective blockers, asthma, ate­
nolol, metoprolol, acebutol, terbutaline, ventilatory 
effects, heart rate 
Nowadays, bela-adrenoceplor blockers are fre­
quently used in the treatment of cardiovascular dis­
ease Since these drugs may induce bronchospasm, 
their use is limited in patients with obstructive lung 
disease This side effect is explained by smooth mus 
ele spasm caused by blockade of the bronchial beta,-
receptors Therefore, the use of non selective beta-
blockers, such as propranolol, is contramdicated in 
asthmatic patients 
brom this point of view the development of beta -
selective blockers, such as atenolol and metoprolol, 
should be advantageous, not only because their influ­
ence on ventilation in asthmatics is limited but also 
because the bronchodilator effect of a bela -stimulal-
ing drug would not be inhibited (Johnsson et al 
\9Ti, Tivenius 1976 Vilsvik and Schaanmng 1476) 
At present, three beta^seleetive bloekers, ate­
nolol, metoprolol and acebutolol are available for 
use in medical practice The aim of our study was to 
compare the ventilatory effects of these three agents 
in asthmatic patients, and their influence on the 
bronchodilating effect of the betai-receptor stimulant 
terbutaline 
Patients and Methods 
The study comprised eight males with bronchial 
asthma, five of whom also had bronchitis Their mean 
age was 33 years (range 20^44 years) All patients 
were free from cardiovascular disease During the 
study, all the patients were in a stable respiratory 
state Their lung function was only slightly abnormal, 
and terbutaline was known to produce at least a 20% 
increase in forced expiratory volume in one second 
(FEV,) during bronchospasm Bronchodilator medi­
cation was discontinued at least one week before the 
study Patients who showed no bronehoeonstnction 
on any of the beta-blockers were excluded All 
patients consented to participate in the study after 
receiving detailed information on its purpose, 
methods and possible side effects 
I he investigations were performed on four dif­
ferent days, separated by intervals of 1-2 days Pla­
cebo was given on the first day On the other days the 
patients received double blind, and in random order 
atenolol 100 mg, metoprolol 100 mg and acebutolol 
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400 mg. The medication was taken at noon during a 
standard meal, which was the same on every day of 
the study. 
Before, and 2, 3 and 4 h after taking the medi­
cation the patients exercised for 5 min on a bicycle 
ergometer (Lode), at a fixed load of 2 watt/kg body 
weight. The heart rate was recorded on a electrocar­
diograph (Hellige) before and during the last minute 
of exercise. The inspiratory vital capacity (VC) and 
FEV, were measured before and 15 mm after exer­
cise with a spirometer (Godart Pulmotest, highest of 
2 readings). Before, during the last minute of exer­
cise and 15 min after exercise peak expiratory flow 
rate (PEFR) was recorded, using a Wright peak flow 
meter (highest of three readings). After the last series 
of measurements, the patients were given terbutalme 
1.5 mg in 6 inhalations. 15 min later heart rate and 
ventilatory indices were again recorded. 
V""^  
\v—" 
2hrs 
""· · 
3 hrs 4 hrs 
ΔΗΡ(/πιιη) # placebo 
Omeloprolol 
100 п-в 
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Fig. 1. Mean changes in exercise heart rate during 
placebo, dtcnolol, metoprolol and accbutolol 2.3 and 
4 h after treatment (ιι = 8) 
Table 1. FEV, und PEFR values before and after exercise and before and 2, 3 and 4 h after administration of placebo, atenolol, metoprolol 
and accbutolol, FEV, and PEFR values after inhalation of terbutalme are also shown (Mean ± SEM, η = Я) 
Before exercise 
FEV, [Ι] 
Placebo 
Atenolol 
Metoprolol 
Accbutolol 
PEFR [l/min] 
Placebo 
Atenolol 
Metoprolol 
Acebulolol 
/5 mm after exercise 
FEV, [1] 
Placebo 
Alenolol 
Metoprolol 
Acebutolol 
PEFR [l/mm] 
Placebo 
Atenolol 
Metoprolol 
Acebutolol 
Initial values 
2 77±0.30 
2 83 ± 0 28 
2 8 8 ± Ü 2 6 
2 8()±0 30 
429±32 
419+35 
443 + 30 
425 + 30 
2 73 ± 0 4 0 
2 7 4 + 0 23 
2 8 l ± 0 22 
2 85 ± 0 28 
428±36 
422±35 
436±27 
425+31 
Values after intake of medication 
2 h 
2.71+0 30 
2 4 3 ± 0 27 
2 46+0 26 
2 5 4 1 0 30 
418 = 36 
378^39 
3 8 6 - 3 7 
389 = 39 
2 65±0 32 
2 4 0 ± 0 25 
2 4 4 x 0 29 
2 4 2 * 0 28 
408 = 40 
374 + 41 
365=40 
381J.37 
31) 
2 8 0 + 0 29 
2 5 1 + 0 23 
2 6 0 ± 0 28 
2 5 6 + 0 29 
421+35 
394 ±35 
193132 
405 + 37 
2 7 4 1 0 11 
2 4 0 + 0 23 
2 4 6 + 0 25 
2 5 2 1 0 28 
423 + 40 
382+40 
3 8 4 1 3 3 
3 8 9 1 4 0 
4 h 
2 6 9 ± 0 30 
2 4 8 + 0 27 
2 5 2 1 0 26 
2 5 3 + 0 28 
4 1 2 1 4 0 
3 8 8 - 3 8 
3 8 1 : 3 4 
3 9 1 : 3 5 
2 6 5 : 0 28 
2.37=0 25 
2 3 9 : 0 23 
2 3 9 : 0 27 
4 0 8 1 3 7 
373+41 
374 + 34 
379+37 
15 min after 
inhalation of 
Terbutaline 
3 36+0 32 
3 0 7 + П 2 8 
3 1710 27 
2 9 1 1 0 30 
506124 
482 + 32 
479 + 25 
460 + 33 
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AFEV, ! l ) -
after 
terbutahne 
Fig. 2. Changes m FEV, before exercise measured 2, j and 4 h 
after intake of placebo, atenolol, metoprolol and acebutolol, and 
after stimulation with terbutaline (Mean ± SEM, /ï = 8) 
Fig. 3. Changes in FEV, after exercise, measured 2. 3 and 4 h after 
intake of placebo, atenolol, metoprolol and acebutolol, and after 
stimulation with terbutaline (Mean ± SEM, н = 8) 
The results are presented as mean ± SEM. Since 
the distribution of the variables presented in the 
study seemed to be normal, statistical analysis was 
done with Student's Mest for paired observations. 
Results 
No significant differences were found between the 
initial values of the measured indices on the four days 
of the investigations. 
The 3 beta-blockers considerably reduced the 
exercise heart rate, whereas there was only a small 
decrease after placebo (Fig. 1); compared with pla­
cebo the reductions in exercise heart rate were highly 
significant (p < 0.001). The reduction in exercise 
heart rate 2 h after ingestion of the tablets was not 
significantly different between the 3 beta-blockers; 
after 3 and 4 h the reduction in exercise heart rate 
caused by acebutolol was more pronounced than that 
due to metoprolol (p < 0.05 and ρ < 0.001, respec­
tively). 
The ventilatory indices are presented in Table 1. 
The FEV j , VC and PEFR measured before and after 
exercise were compared with their corresponding in­
itial values before ingestion of the tablets. Compared 
with the initial values, the 3 beta-blockers caused a 
significant reduction in FEVj and PEFR 2, 3 and 4 h 
after ingestion of the medication, both before and 
after exercise (Table I ; Figs. 2 and 3). The effect of 
Table 2. Changes in PEFR during and after exercise from the 
pre-cxcrcise values measured 2 h after treatment (Mean ± SEM, 
it - 8) 
Placebo Atenolol Metoprolol Acebutolol 
Δ PEFR during 
exercise [1'minj +75±16 -"-71110 +623.10 +63+13 
Δ PEFR after 
exercise [1 mm] - 1 0 ± 5 - 4±12 -21±15 - 8± 8 
the medication on the VC was much less pronounced. 
No significant differences were found between the 3 
beta-blockers with regard to their effects on VC, 
FEV, and PEFR. 
The 3 beta-blockers reduced the PEFR values 
during exercise to the same extent as the values 
measured before and after exercise. At every time 
during placebo and beta-blockade, exercise caused 
an increase in PEFR (Table 2). There were no 
significant differences between these values. 
The falls in PEFR after exercise compared to the 
values before exercise were the same during placebo 
as during beta-blockade, i. e. the beta-blockers did 
not cause any increase in exercise-induced broncho-
spasm (Table 2). 
After administration of the beta_,-receptor-
stimulant terbutaline, there was a considerable rise in 
FEV, and PEFR (Figs. 2 and 3). The increases in 
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AFEV, (I : 
1.0- » p<005 
· » » p<0001 
I I placebo 
CZ3 aîenolo 
I', Τ ñ metoprolol 
acebutoiol 
before after exercise 
Fig. 4. Terbutalme-induced changes in FEV, 4 h after ingestion of 
medication, both before and after exercise {Mean + SEM. /? = 8) 
FEV, compared with the values 4 hours after intake 
of the tablets, measured before and after exercise, 
are presented in Fig. 4. The FEV, rise after 
acebutolol appeared to be significantly less than after 
atenolol and metoprolol. 
Discussion 
The study was performed in asthmatic patients with a 
good response to terbutaline, because there are indi-
cations that in these patients beta-blockers can 
induce bronchospasm, in contrast to patients with 
fixed bronchial obstruction, as in chronic bronchitis 
(Nordström et al. 1975; Perks et al. 1978; personal 
observations). Because the aim of the study was to 
compare the ventilatory effects of betapselective 
blockers, patients who did not show bronchial 
obstruction after any of the beta-blockers were 
excluded. 
In this study the beta-blockers were administered 
orally, because it is the usual route of administration 
to patients, and it has been shown that, after oral 
administration of acebutolol, the metabolite N-acetyl 
acebutolol makes a considerable contribution to the 
pharmacological effect (Collins 1975). To avoid dif-
ferences in absorption, the medication was adminis-
tered during a standard meal (Melander 1978). 
The three beta-blockers produced the same 
reduction in exercise heart rate 2 h after ingestion of 
the medication, so it can be stated that the medica-
tion was used in cardiac equipotent doses. The effect 
of acebutolol on exercise heart rate persisted longer, 
which can be explained by its longer half life, or by 
the effect of its N-acetyl metabolite. Our findings 
concerning the cardiac effects of the beta-blockers 
are in agreement with other studies (Collins 1975; 
Johnsson and Regârdh 1976). 
In our patients the three beta-blockers caused an 
increase in bronchospasm, shown by a decrease in 
FEV, and PEFR. There was no difference in the ven-
tilatory effects of the three agents before and after 
exercise at any times. According to the classification 
of Lands et al. (1967), beta-receptors can be divided 
into two subgroups, beta, for cardiac and beta, for 
bronchial and vascular receptors. In animal experi-
ments, however it has been established that absolute 
separation in organs of beta,- and beta2-receptors 
does not exist (Carlsson et al. 1972; Lulich et al. 
1976; Barnett et al. 1978). The airways, for example, 
possess both beta,- and beta,-receptors, both of 
which may cause bronchodilatation after stimulation. 
Thus, the bronchoconstriction induced by a beta-
blocker may result from blockade of beta,- or beta,-
receptors, which explains why beta,-selective block-
ers can also induce bronchoconstriction. Based on 
the effect of the beta-blockers on the ventilatory 
indices alone, nothing can be concluded about the 
selectivity of a beta-blocker. 
The selectivity of the beta-blockers used can be 
judged by their influence on the bronchodilator 
effect of a bcta,-receptor stimulating drug. The 
stimulant effect of terbutaline on FEV, and PEFR 
during placebo, atenolol and metoprolol was equal, 
but it was diminished after acebutolol (Fig. 4). This 
observation may indicate greater occupation of the 
beta,-receptors during acebutolol medication, and so 
point to lower selectivity of acebutolol for beta,-
receptors compared to atenolol and metoprolol. 
Leary et al. (1973) and Skinner et al. (1975) have 
reported similar observations. It is not known 
whether the lower selectivity of acebutolol is caused 
by acebutolol itself or its N-acetyl metabolite. 
During exercise there is generally an increase in 
bronchodilatation, possibly caused by increased sym-
pathetic tone (Lefcoe 1969). This explains the 
increase in PEFR during exercise recorded in this 
study. The three beta-blockers decreased PEFR 
before and during exercise to the same extent, but 
they did not show any influence on the increase in 
PEFR caused by exercise. Also, the non-selective 
beta-blocker propranolol showed no effect on the 
increase in PEFR during exercise (Van Herwaarden 
et al. 1979). These findings suggest that the bron-
chodilation caused by exercise is not mediated by 
stimulation of bronchiolar beta-receptors but via 
another mechanism. 
The ventilatory indices were also recorded after 
exercise, because exercise can provoke an asthmatic 
attack. This phenomenon is known as exercise-
induced asthma and is caused by cooling of the air-
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ways (McFadden and Ingram 1979) The decrease in 
PEER was almost the same before and after exercise, 
during placebo and beta-blockade, which suggests 
that exercise-induced asthma is not benefited by 
betapselective blockade 
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Ventilatory and Haemodynamic Effects of Terbutaline Infusion 
During Betaj-Selective Blockade with Metoprolol and Acebutolol 
in Asthmatic Patients 
А Р М Greefhorst* dnd С L A van Herwaarden 
Universityof Nijmegen H Landstichtmg The Netherlands Department of Pulmonary Diseases Medical Centre Dckkerswald 
Summary. A double-blind, placebo-controlled study 
of the haemodynamic and ventilatory effects of two 
betai-selective adrenoceptor blockers and their inter­
action with the betaj-adrenoceptor agonist terbuta-
hne was earned out in eight asthmatic patients One 
hour after intake of placebo, metoprolol 100 mg or 
acebutolol 400 mg, increasing doses of terbutalme 
were infused Before and one hour after ingestion of 
the medication and after each infusion of terbuta­
lme, ventilatory and haemodynamic indices were 
measured The two beta blocking agents caused 
equal changes in basal ventilatory and haemody­
namic indices Terbutalme infusion caused a dose-
dependent increase in forced expiratory volume in 
one second (FEV,) and peak expiratory flow rate 
(PEFR), both during placebo and beta-blockade 
Metoprolol did not affect the terbutahne-induced 
bronchodilatation During acebutolol medication, 
however, the increase in FEV, and PEFR induced by 
terbutalme was partly inhibited Terbutalme infusion 
during placebo caused a dose-dependent increase in 
heart rate (HR) and systolic blood pressure (BP), and 
a decrease in diastolic BP Dunng acebutolol medi­
cation, these haemodynamic effects of terbutalme 
were completely blocked, but dunng metoprolol 
medication terbutalme still caused small changes in 
the same direction as dunng placebo, presumably 
because the vasodilator action of terbutalme was not 
inhibited A negative correlation was found between 
the plasma levels of acebutolol and its metabolite N-
acetyl acebutolol at the end of the study and changes 
in FEVi and PEFR induced by terbutalme dunng 
acebutolol therapy as compared with placebo The 
ventilatory and haemodynamic findings suggest a 
* Present address St Gerardus Maiella ziekenhuis Kortenaer 
straat 3, NL 7556 Dt Hengelo (Ov) The Netherlands 
lower degree of bctai-sclcctivity after oral adminis­
tration of acebutolol as compared to metoprolol 
Key words: beta,-selective blockers, asthma, terbuta 
line infusion, metoprolol, acebutolol, ventilatory ef­
fects, heart rate, blood pressure, plasma levels 
A well-known side effect of beta-adrenoceptor 
blockers is bronchospasm, especially in patients with 
obstructive lung disease The influence of betapse 
lective blockers on ventilation in these patients is less 
than that of non-selective beta-blocking agents 
(Johnsson et al 1975, McGavin and Williams 1978) 
Moreover, the bronchodilator effect of beta-sym-
pathicomimetic agents is virtually unaffected during 
betai-selcctive blockade, but it is almost completely 
inhibited dunng non-selective beta-blockade (Johns-
son et al 1975, Thinnger and Svedmyr 1976) These 
findings warrant the use of a betai-selective agent, 
alone or in combination with a beta2-receptor stimu­
lant, in patients with obstructive lung disease, if 
treatment with beta-blockers is indicated 
In a comparative study of the ventilatory effects 
of three betapselective blockers, it was shown that 
the bronchodilator response to terbutalme inhalation 
was partly inhibited dunng acebutolol medication in 
contrast to placebo, atenolol and metoprolol (Greef­
horst and Van Herwaarden 1981) These findings 
suggest a lower degree of bela^selectivity of acebut­
olol for the bronchiolar beta2-receptors, which might 
also be applicable to the vascular beta2-receptors 
Accordingly, a study has been made of the ventilato­
ry and haemodynamic effects of terbutalme infu­
sions dunng treatment of asthmatic patients with 
metoprolol and acebutolol 
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Tabic 1. Characteristics of the patients in the study 
Subject Age Sex Height 
no (years) (cm) 
Weight 
[kg] 
FfcV, 
Actual 
[1] 
% of Pre­
dicted values 
% of Increase 
with lerhulalme 
Treatment for 
asthma* 
34 
46 
26 
22 
20 
19 
37 
25 
M 
F 
M 
M 
M 
M 
F 
M 
179 
167 
203 
174 
167 
180 
163 
174 
69 
65 
74 
64 
60 
71 
62 
64 
31 
23 
3.6 
2.9 
27 
2 1 
2 0 
2 7 
89 
89 
69 
80 
82 
51 
82 
74 
24 
23 
28 
32 
32 
54 
51 
43 
CT 
С 
Τ 
τ 
τ 
CBS 
г 
CT 
С — cromoglycate Τ - terbutaline as needed В = beclomethasone S — salbutamol as needed 
Δ FEV, 
dl 
ш—
 0ï 
и 
Systole blood pressure Ooslolic blood pressure 
(mm Hg) (mmHg ) 
-у^ 
0 Plocebo 
G Metoprolol 
5 Acebutolol 
• p < 0 0 5 
· · p<001 
· » · p<0001 
Flg.l. Changes in FEV,, heart rate and blood pressure measured 
1 hour after intake of placebo, metoprolol and accbutolol (Mean 
± SEM, η = 8) 
Patients and Methods 
The study comprised 2 female and 6 male asthmatic 
patients; for clinical details see Table 1. Their mean 
age was 29 years. All patients had extrinsic atopic 
asthma, all had eosinophilia and one or more posi­
tive skin tests. None had cardiovascular disease. 
During the study, all the patients were in a stable re­
spiratory state. Direct bronchodilator agents were 
discontinued at least one week prior to the study. 
Four patients continued using disodium cromogly­
cate and/or beclomethasone dipropionate. All pa­
tients showed an increase of at least 20% in FEV, 
during the first day of the study upon infusion of the 
beta2-receptor stimulator terbutaline during the 
placebo period. All patients consented to participate 
in the study after receiving detailed information 
about its purpose, methods and possible side effects. 
The design of the study was approved by the Ethical 
Committee of the University of Nijmegen. 
The patients were examined on three different 
days, each seperated by at least one day. All investi­
gations started at 2.00 p.m. Placebo was given on the 
first day. On the second and third days the patients 
were given metoprolol 100 mg or acebutolol 400 mg 
orally in a double-blind random manner. All meas­
urements were performed with the patients sitting. 
Before and one hour after intake of the tablets, the 
ventilatory indices FEV,, inspiratory vital capacity 
(VC; Godait Pulmotest, highest of two readings) and 
PEFR (Wnght peak flow meter, highest of three 
readings) were measured. The HR was recorded us­
ing an electrocardiograph (Hellige), and the BP was 
measured with a Physiometrics SRII. Next, the ven­
tilatory and haemodynamic effects of an infusion of 
terbutaline were studied. Terbutaline was infused in­
to a cubital vein every 30 min, over a 5-min period, in 
doses of 0.0625,0.125,0.25 and 0.5 mg, using an infu­
sion pump (Vickers Medico, Treonic IP3). The venti­
latory and haemodynamic indices were reassessed 
3 min after infusion of each dose. 
One hour after ingestion of the beta-blockers and 
1.5 h later, after the last series of measurements, 
blood samples were taken for determination of the 
plasma levels of the agents and their metabolites. 
Plasma metoprolol was measured by gas chromatog­
raphy according to Ervik (1975), and the plasma lev­
els of acebutolol and its N-acetyl metabolite were de­
termined by high pressure liquid chromatography 
according to Holt et al. (1981). Blood samples were 
stored at — 20 "C until analysed. 
The results are presented as mean ± SEM. The 
mean arterial pressure (MAP) was calculated by ad­
ding one-third of the pulse pressure to the diastolic 
BP. 
Since the distribution of the variables presented 
in this study appeared to be normal, statistical analy-
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Table 2. EITecIs оГасеЬшоІоІ and metoprolol on FCV, and PEFR, and the changes in these indices induced by tcrbutalme infusion 
FEV, [1] Placebo Metprolol Acebulolol ρ placebo ρ placebo ρ meloprolol 
versus versus versus 
metoprolol acebutolol acebutolol 
0 hour 
1 hour 
efTect ofterbutalme 
1 dose 
2 dose 
3 dose 
4 dose 
2 68± 
266± 
0 38± 
0 71± 
0 84± 
0 93± 
019 
019 
0 08 
011 
0 10 
010 
2 60± 
2.37 ± 
0.24 ± 
047 ± 
0 74± 
0 94± 
016 
0.16 
006 
011 
011 
0 13 
2 68± 
245 ± 
017 + 
0 3 1 ± 
0 45± 
0 60± 
0 21 
0 21 
0 02 
0 07 
009 
011 
NS 
NS 
NS 
NS 
< 0 05 
< 0 05 
< 0 05 
< 0 05 
NS 
NS 
NS 
< 0 05 
PEFR[l/minJ 
Ohour 
1 hour 
elTect ofterbutalme 
Idose 
2 dose 
3 dose 
4 dose 
415 
410 
+ 41 
+ 83 
+ 96 
+ 106 
± 2 7 
± 3 1 
± 1 2 
± 1 4 
± 1 5 
± 1 4 
394 
164 
+ 28 
+ 67 
+ 102 
+ 126 
± 2 9 
± 2 9 
± 1 0 
± 1 3 
± 1 2 
± 1 6 
388 
370 
+ 6 
+ 34 
+ 50 
+ 73 
± 3 1 
± 3 2 
± 1 0 
± 1 1 
± 1 4 
± 1 7 
NS 
NS 
NS 
NS 
< 0 05 
< 0 001 
< 0 01 
< 0 0 1 
NS 
NS 
< 0 05 
< 0 05 
Mean ± SEM η = 8 NS - not significant 
sis was done with the Student /-test for paired obser­
vations. Correlations were calculated according to 
Pearson. 
Results 
No significant differences were found between the 
initial values of the indices measured on the different 
days of the study. 
The effects of the two beta-blockers on the initial 
values of the most important indices are shown in 
Fig. 1. The two beta-blockers caused an approxi­
mately equal, significant decrease in FEV,, PEFR, 
HR and systolic BP. The VC, MAP and diastolic BP 
remained unchanged. No significant differences 
were found between the effects of the two beta-
blockers on these indices. 
The values of FEV, and PEFR before and one 
hour after ingestion of the beta-blockers, and the 
changes in these indices induced by terbutalme, are 
presented in Table 2 and Fig. 2. The different doses 
of terbutaline caused a constant rise in FEV, and 
PEFR during placebo, metoprolol and acebutolol. 
The effects of terbutaline on FEV, and PEFR were 
not significantly different during medication with 
placebo and metoprolol. During acebutolol treat­
ment, however, the increases in these indices were 
significantly less marked than those during placebo. 
The changes in FEV, after the last dose, and in 
PEFR after the last two doses of terbutaline, were al­
so significantly less marked during acebutolol than 
during metoprolol medication. The changes in VC 
were much less pronounced. 
t im· (h) 
Flg.2. Changes in FEV, induced by terbutaline infusion during 
placebo, meloprolol and acebutolol (Mean ± SEM, л - 8, ρ val­
ues versus placebo) 
The effects of terbutaline infusion on haemody-
namic indices are shown in Fig.3. During placebo, 
terbutaline caused an increase in HR and systolic 
BP, and a decrease in diastolic BP, while the MAP 
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η il ü 
Fig.3. Changes in heart rate and blood pressure induced by terbutalme infusion dunng placebo, metoprolol and acebulolol (Mean, 
M = 8) 
Table 3. Plasma levels of metoprolol, acebulolol and its N-acet>l 
metabolite 1 and 2 5 hours after treatment 
1 h after 
intake of medication 
range 
2 5 hours after 
intake of medication 
ρ values versus 
I h 
range 
Acebutolol 
[mg/l] 
0 2 8 ± 0 0 7 
0 0 3 - 0 5 9 
047 ± 0 0 8 
NS 
0 1 6 - 0 9 1 
N-acetyl 
acebulolol 
[mg/l] 
0 2 0 ± 0 0 6 
0 03- 0 52 
055 ± 0 11 
p < 0 0 1 
0 0 9 - 0 8 9 
Metoprolol 
[nmol/I] 
285 ± 123 
10-830 
339 ± 66 
NS 
10-580 
Mean ± SEM π - 8 
remained unchanged. During beta-blockade the 
haemodynamic effects of the smaller doses of terbut-
aline were almost completely absent. Infusion of the 
largest dose of terbutalme during metoprolol medi­
cation caused a significant rise in HR and systolic 
BP, and a decrease in diastolic BP. During acebulo­
lol medication, even the largest dose of terbutaline 
caused no significant change in HR or in systolic and 
diastolic BP. Comparison of the haemodynamic ef­
fects of terbutaline during medication with metopro­
lol and acebutolol, however, revealed no significant 
differences. 
The plasma levels of both beta-blockers are pre­
sented in Table 3. The plasma metoprolol levels one 
hour after treatment were not significantly different 
from the values obtained at the end of the study; 
1.5 h later. The plasma acebutolol levels one hour 
after intake of the tablet, too, were not significantly 
different from the levels obtained at the end of the 
study, but the plasma N-acetyl acebutolol levels in­
creased significantly (p < 0.01) during this period. 
The quotient of the increase in ventilation caused 
by terbutaline during beta-blockers and placebo 
/change in ventilation during beta-blockade\ 
\ change in ventilation dunng placebo / 
used in calculation of correlations with plasma levels 
of both drugs, because this quotient probably ex­
presses the degree of betai-selectivity of a beta-
blocker. 
There was a negative correlation between this 
quotient for the FEV, and the plasma levels of ace­
butolol (r = -0.77 ρ < 0.05), N-acetyl acebutolol 
(r = —0.71 ρ < 0.05) and the sum of both plasma 
levels (r = - 0.76 ρ < 0.05). This quotient for PEFR 
was also negatively, correlated with the plasma ace­
butolol level (r - -0.77 ρ 0.05), but not with the 
plasma N-acetyl acebutolol level (r = — 0.48) or the 
sum of both plasma levels (r = —0.62). No relation­
ship was found between the plasma metoprolol level 
and these ventilatory indices. 
Changes in haemodynamic indices were not re­
lated to the plasma levels of the two beta-blockers, 
neither for the values one hour after intake of medi­
cation or those at the end of the study. 
Discussion 
The study was carried out in asthmatic patients with 
an increase of at least 20% in FfcV, after stimulation 
with the beta^-receptor agonist terbutaline, which in­
dicates that the bronchodilatation was mediated via 
stimulation of the beta-receptors in the smooth mus­
cles of the airways. Only in such asthmatic patients 
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can bela-blockers be expected to induce broncho-
spasm (Perks et al 1978, personal expenence) Tore-
duce basal variation in lung function, and to avoid 
the morning dip in ventilation in asthmatics, all 
measurements were performed in the afternoon 
(Connolly 1979) Patients who showed more than 
10% variation in the initial ventilatory indices were 
excluded from the study It was not possible to show 
that the beta-blockers were administered in a equi-
potent doses in terms of their cardiac effects, because 
no exercise test was performed In a previous study, 
however, it was shown that these doses ofmetoprolol 
and acebutolol were practically equipotent at the 
time the measurements were perlormed (Greefhorst 
and Van Herwaarden 1981) 
The two beta-blockers caused an equal increase 
in bronchospasm, as shown by a small decrease both 
in FEV, and PfcFR, while VC was unaffected 
The selectivity of the beta-blockers used can be 
judged b> measuring their influence on the bron-
chodilator effect of a beta; receptor stimulant, such 
as terbutahne (Johnsson et al 1975) For this purpose 
terbutalme was infused in increasing doses During 
placebo, terbutalme caused a marked increase in all 
ventilatory indices at almost every dosage used, as 
was expected in asthmatic patients with reversible 
airways obstruction During mctoprolol medication, 
the bronchodilator effect of terbutalme infusion was 
virtually the same as during placebo (Fig 2), reveal­
ing that the beta^-receplors in the airways were not 
occupied b> metoprolol During acebutolol medica­
tion, however, the bronchodilator effect of terbuta­
lme was partly inhibited After oral ingestion of ace­
butolol, betai-receptors seemed to be occupied to a 
certain extent and only larger doses of terbutalme 
can supersede acebutolol on those receptors Since 
there was a significant difference in the ventilatory 
effect of terbutalme during metoprolol and acebuto­
lol medication, the affinity of acebutolol or its me­
tabolite N-acetyl acebutolol for the beta^-receptor in 
the airways appears to be greater than that of metop­
rolol, which means that acebutolol and/or its metab­
olite has a lower degree of beta,-selectivity than met­
oprolol These findings are in agreement with previ­
ous observations after inhalation of terbutalme 
(Greefhorst and Van Herwaarden 1981) 
In this acute experiment the beta-blockers caused 
a decrease in HR and systolic BP, while the diastolic 
BP remained unchanged (Fig 3) These haemody-
namic changes can be explained by a diminution in 
cardiac output Acute beta-blockade has no marked 
effect on diastolic BP, due to an increase in peripher­
al resistance, which disappears on continuation of 
treatment (Hansson et al 1974, Tarazi and Dustan 
1972) 
Terbutalme infusion during placebo caused a 
marked increase in HR and systolic BP, and a de­
crease in diastolic BP, the MAP remained un­
changed Terbutalme causes vasodilatation by stimu 
lating the vascular beta^receplors (Sackner et al 
1975, Sharma and Goodwin 1978, Teule and Majid 
1980), and this can account for the decrease in dia­
stolic BP in the patients A decrease in MAP, how­
ever, is counteracted by the baroreceptor reflex, 
which results in increased sympathetic tone, causing 
an increase in HR, systolic BP and pulse pressure via 
stimulation of the cardiac beta-receptors The extent 
to which terbutalme also directly stimulates the car­
diac receptors and increases these indices remains 
obscure 
During metoprolol medication there was a signif­
icant increase in HR and systolic BP, and a decrease 
in diastolic BP only alter the larger doses of terbuta­
lme It has been established that the vasodilatation 
mediated via the vascular betai-receptors remains 
partly intact during betapselective blockade (Johns-
son et al 1975 Van Herwaarden et al 1977) The de­
crease in diastolic BP induced by terbutalme during 
medication with metoprolol should be regarded as 
betaï-receptor-mediated vasodilatation As the cardi-
ac effect of increased sympathetic tone mediated via 
the baroreceptor reflex is abolished by metoprolol, 
only a small increase m HR and systolic BP was 
seen 
During acebutolol medication, terbutalme infu-
sion caused no significant change in the haemody-
namic indices measured The vasodilator effect of 
terbutalme during acebutolol medication was appar 
ently blocked, which may indicate greater occupa-
tion of betai-receptors in muscle vessels and a lower 
degree of beta, selectivity Since no significant dif-
ference in the haemodynamic effects of infused ter-
butalme during metoprolol and acebutolol medica-
tion was found, no final conclusion can be reached 
regarding the betapselectivity of these two agents on 
haemodynamics 
The plasma levels of both beta-blockers showed 
a wide range (Table 3) This is a well-known 
phenomenon during treatment with beta-blockers 
and does not necessarily indicate the same variation 
in pharmacological effect (Winkle et al 1977, Van 
Herwaarden et al 1979) Since acebutolol is trans-
formed to an active metabolite (Collins 1975), the 
plasma level of this metabolite (N-acetyl acebutolol) 
was also measured There was no significant differ-
ence between the plasma acebutolol levels 1 and 
2 5 h after intake of the tablet, but the plasma N-ace-
tyl acebutolol level increased significantly during the 
study This suggests quick transformation of ace-
butolol to its metabolite after oral ingestion After in-
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travenous administration of acebutolol, the plasma 
levels of the N-acetyl metabolite are lower (Meffin et 
al. 1976), indicating that acebutolol is probably 
transformed in the liver. It has been demonstrated in 
dogs that acebutolol is only transformed to N-acetyl 
acebutolol to a minor degree after oral administra­
tion, probably due to inhibition of the enzyme aryl-
amine acetyl transferase in dogs (Winkle et al. 1977). 
No conclusion about betai-sclcctivity of acebutolol 
in human subjects can be derived from animal exper­
iments or measurements after intravenous adminis­
tration The correlations found in the present study 
between the plasma levels of acebutolol and its me­
tabolite and the diminished terbutaline-induced 
changes in ventilatory indices are a further indica­
tion of the lower degree of betai-selectivity of ace­
butolol and/or its metabolite as compared to meto-
prolol. 
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Ventilatory and Haemodynamic Effects of Prenalterol 
and Terbutaline in Asthmatic Patients 
А Р М Greefhorst* and С L A van Herwaarden 
Department of Pulmonary Discases Uni\ersity of Nijmegen Medical Centre Dekkerswald, H l^ndstichling, Піе Netherlands 
Summary. In 8 asthmatic patients a comparative 
study was performed of the ventilatory and haemo­
dynamic effects of the beta,-receptor stimulator pre­
nalterol and the beta^-receptor stimulator terbutaline 
infused in increasing doses after a placebo Terbuta­
line caused a dose-dcpcndcnt decrease in diastolic 
blood-pressure (BP) and an increase in systolic BP 
and heart-rate (HR), while mean arterial pressure 
(MAP) did not change Prenalterol produced a dose-
dependent increase in MAP and systolic BP, while 
diastolic BP was unaffected HR was increased only 
by the largest dose of prenalterol The haemodynam­
ic effects of the terbutaline infusion can be explained 
by a reflex response to the vasodilatation induced by 
stimulation of the vascular bcta2-receptors, while the 
effects of prenalterol can mainly be accounted for by 
a direct action on beta,-receptors in the heart These 
observations show that the cardiac side-effects of be 
ta?-agonists cannot be avoided by producing more 
selective agonists Terbutaline caused a dose-de­
pendent increase in the ventilatory indices Prenal­
terol in larger doses caused a limited but significant 
increase in the ventilatory indices, comparable to the 
decrease in ventilation caused by the betai-selcctive 
blocker metoprolol These findings suggest that the 
ventilatory effects of metoprolol and prenalterol are 
mediated via beta preceptors in the airways, which 
apparently play a functional role in asthma 
Key words: terbutaline, prenalterol, asthma, metop­
rolol, haemodynamic effects, ventilatory effects, 
comparative trial, bronchial ßrreeeptors, selective β-
blockers 
* Present address Streekziekenhuis Midden Twente, afd St Ger 
ardus Majella Kortenaerstraal 3, NL 7556 DA Hengelo (Ov) The 
Netherlands 
In the late 1960s, beta->-selective adrenoceptor agon­
ists were developed for the treatment of broncho-
spasm in asthmatic patients, because their undesir­
able influence on the cardiovascular system was ex­
pected to be limited Although the effect of these be­
tas-selective agonist on heart preparations in vitro 
was considerably less than that of the non-selective 
beta agonist isoprenalme (Broadly and Nicholson 
1979), the betas-selective agonists still caused a clear 
increase in HR in vivo In clinical practice tachycar­
dia after oral administration of betas selective agon­
ists is a well known side effect The tachycardia can 
be explained by direct stimulation of beta-receptors 
in the heart, because beta selectivity of these drugs is 
thought to be only relative Another possible expla­
nation of the tachycardia is a reflex mechanism via 
the baroreceptors in response to the vasodilatation 
induced by stimulation of the vascular betas-recep­
tors 
Betapselective adrenoceptor antagonists were 
developed in the 1970s because their influence on 
ventilation in asthmatic patients was expected to be 
limited It has since been established, however, that 
even beta, selective antagonists can induce an in­
crease in bronchospasm in asthmatic patients (Van 
den Bergh and Van Herwaarden 1981, Greefhorst 
and Van Herwaarden 1981) This decline in ventila­
tion can be explained by the relative betai-selectivity 
of these drugs Another explanation comes from the 
fact that the airways possess betai-receptors in addi­
tion to their preponderant betas receptors (Lulich et 
al 1976, Barnettetal 1978) Prom this point of view 
a betai-selective antagonist might cause a decrease in 
ventilation in asthmatic patients by blockade of the 
beta ι-receptors in the airways On the other hand, a 
betai-selective agonist might be expected to induce 
an increase in pulmonary function in asthmatic pa­
tients 
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Table I. С haractenstics of the patients in the study 
Subject Age Sex Height Weight 
no bears] [cm] [kg] 
14 
46 
26 
22 
20 
19 
37 
25 
M 
F 
M 
M 
M 
M 
F 
M 
179 
167 
203 
174 
167 
180 
161 
174 
69 
65 
74 
64 
60 
71 
62 
64 
d
 С = cromogl>cate, Τ = terbutaline as needed, В = 
Against this background it was of interest to 
study the ventilatory and haemodynamic effects of 
the beta2-selective agonist terbutaline, the betar 
selective agonist prenalterol and the betapselective 
antagonist metoprolol in asthmatic patients. Prenal­
terol has only recently been developed and has been 
characterised as a non-selective beta-adrenoceptor 
ligand, with a selective partial agonist activity on 
beta,-receptors in the cardiovascular system (Carls-
son et al. 1977; Manders et al. 1980) and the airways 
(Johansson and Waldeck 1981). 
Patients and Methods 
Two female and 6 male asthmatic patients were in­
vestigated; mean age was 29 years (range 19 46 
years). All patients had atopic extrinsic asthma with 
eosinophiha and one or more positive skin tests. 
None of the patients had cardiovascular disease. 
During the study all patients were in a stable respira­
tory state. Their ventilation was moderately dis­
turbed, with an increase of at least 20% in forced ex­
piratory volume in 1 s (FEV,) during maximal betai-
agonist stimulation. Details of the patients are given 
in Table 1. All direct bronchodilator medication was 
discontinued at least 1 week prior to the study. Four 
patients continued using cromoglycate and/or bec-
lomethasone. All assessments were done in the after­
noon. The patients agreed to participate in the study 
after receiving detailed information about its pur­
pose, methods and possible side effects. The study 
design was approved by the Ethical Committee of 
the University of Nijmegen. 
The patients were investigated on 3 different 
days, each separated by at least 1 day. On the first 
day they received metoprolol 100 mg p. о. and on the 
second and third days placebo was given. Before and 
FEV Treatment 
S o f 
Predicted 
\alues 
89 
89 
69 
80 
82 
51 
82 
74 
O
o of Increase 
with 
terbutahne 
24 
23 
28 
32 
32 
54 
51 
43 
asthn 
CT 
С 
Τ 
Τ 
Τ 
CBS 
τ 
CT 
:, S = salbutamol as needed 
1 h after ingestion of the tablets the ventilatory in­
dices FEV,, inspiratory vital capacity (VC; Godart 
Pulmotest, highest of 2 readings) and peak expirato­
ry flow rate (PEFR; Wright peak flowmeter, highest 
of 3 readings), and the haemodynamic indices HR 
(Hellige ECG machine), and BP (Physiometrics SR 
II) were assessed. The Physiometrics SR II is a de­
vice which detects the low frequency vibrations (16 
to 33 Hz) of the Korotkoff sounds via a microphone 
placed under a rigid cuff. It produces reliable blood 
pressure readings (Sime et al. 1975, Van Herwaarden 
et al. 1979). Mean arterial pressure (MAP) was calcu­
lated by adding 1/3 of the pulse pressure to the dia­
stolic BP. 
Subsequently, the ventilatory and haemodynam­
ic effects of infusion of the beta^-agonist terbutaline 
and the beta,-agonist prenalterol were studied. On 
the second day terbutaline was infused every half 
hour via a cubital vein, in doses of 0.0625,0.125,0.25 
and 0.5 mg, each for 5 min. On the third day prenal­
terol was infused every half hour in doses of 0.5,1.0, 
2.0 and 4.0 mg for 5 min penods Between 3 and 
20 mm after each infusion, measurements were per­
formed in the following order· heart rate, blood pres­
sure and finally the ventilatory indices. Because 
pharmacokinetic data have shown that terbutaline 
and prenalterol are rapidly distributed in the body, 
these time intervals were considered suitable for 
asessment of the indices (Thiringer and Svedmyr 
1976; Leferink 1979; Ronn et al. 1979; Scott et al. 
1979). 
After the least series of measurements and during 
metoprolol medication 1 h after ingestion of the tab­
let, a blood sample was taken for determination of 
the plasma levels of the drugs. Samples were stored 
at -20°C until analysis. Metoprolol was determined 
by gas chromatography (Ervik 1975), terbutaline was 
determined by gas chromatography-chemical ioniza­
tion mass spectometry (Jacobsson et al. 1980), and 
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Δ blood pressure 
(mm Hg) 
Δ FEV, 
IO ЮН 
Δ heort role 
(beoli/min) 
20 -j 
Mean Arlinol Pressure 
Diastoltc Pressure 
^ TerbutoLine ffig/iv 
• ρ < 0.05 
• · p<001 
» • ρ < dOQI 
• p<Q0$ 
• · ρ < 0.01 
< · · > ρ<0001 
' ^ · · · · p<Q0001· · · 
Û V C 
( l 1
 аз J 
Terbuloline mg/iv 
Л FEV, 
Δ blood pressure 
(mmHg) 
0 5 
Systolic Pressure 
Meon Arterial Pressure 
* Oioslolic Pressure 
4.0 
^ Pfertotterol mg/iv К Prenalterol mg/iv 
Flg.l. Mean changes in heart rate and bloodpressure after infu- Fig. 2. Mean changes in FEV,, PEFR and VC after infusion of 
sion of prenalterol or lerbulaline (л = 8) prenalterol or terbutahne (л — 8) 
prenalterol was assayed by a combination of gas 
chromatography and mass spectometry (Ervik et al. 
1982). 
All values are presented as mean ± SEM. Since 
the values appeared to be normally distributed, sta­
tistical analysis was done with Student's i-test for 
paired observations. Correlations were calculated 
according to Pearson. 
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Table 2. Changes in ventilatory indices induced by infusion of 
prenalterol and ierbutalinc(medn±SFM, n — 8) 
FEV, [1] 
Oh 
I h 
Л 1 dose 
Δ 2 dose 
Λ 3 dose 
Λ 4 dose 
PLrR[l/minJ 
Oh 
I h 
Δ 1 dose 
Λ 2 dose 
Λ 3 dose 
Δ 4 dose 
VC[I] 
Oh 
I h 
Δ 1 dose 
Δ 2 dose 
Δ 3 dose 
Л 4 dose 
Terbuialmc 
2.68 ±0.19 
2 6 6 ± 0 1 9 
+ 0 3 8 ± 0 0 8 
+ 0 7 1 + 0 1 1 
+ 0 8 4 1 0 1 0 
+ 0 9 3 ± 0 1 0 
415 + 27 
410±31 
+ 41 ±12 
+ 8.1+15 
+ 96±15 
4 106±14 
4 7 ± 0 4 
4 7 ± 0 4 
+ 0 2 ± 0 1 
+ 0 2 ± 0 1 
+ 0 2 + 0 1 
+ 0 3 ± 0 1 
Prenalterol 
2 7 5 ± 0 1 7 
2 7 8 ± 0 1 8 
- 0 0 4 ± 0 0 4 
+ 0.09 + 0 05 
+ 008±OOR 
+ 0 18±005 
414±29 
413 ±25 
- 6 ± 8 
+ 3 + 7 
+ 20± 8 
+ 22 ±10 
4 7 ± 0 4 
4 7 ± 0 4 
0 0 ± 0 0 
+ 0 1 ± 0 0 
+ 0 2 ± 0 0 
+ 0 3 ± 0 1 
Results 
The initial values of the assessed indices on the dif­
ferent days of the study were not significantly differ­
ent. 
Administration of metoprolol on the first day of 
the study caused a small increase in broncho-
constriction, shown by a decrease in FEVj of 0.23 ± 
0.061 (p<0.01) and PEFR of 30±121/min (p< 
0.05); there was no significant change in VC. Meto­
prolol caused a decrease m HR of 9±4bpm (p< 
0.05) and in systolic BP of 14±4mm Hg (/?<0.01), 
whilst diastolic BP and MAP were unchanged. 
The effects on haemodynamic indices of terbuta-
line and prenalterol are presented in Fig. 1. Terbuta­
line infusion induced a marked increase in HR and 
systolic BP and a decrease in diastolic BP. The MAP 
remained unchanged. Prenalterol caused a marked 
increase in systolic BPand MAP, leaving the diastol­
ic BP unchanged. There was only a small increase in 
HR after infusion of the largest dose of prenalterol. 
The ventilatory indices and the changes induced 
by terbutaline and prenalterol are shown in Table 2 
and Fig. 2. Terbutaline resulted in a highly signifi­
cant dose-dependent- increase in FEV,, PEFR and 
VC. Prenalterol infusion, however, also caused a 
small increase in FEV,, which was significant only 
after infusion of the largest dose of 4 mg. The in­
crease in PEFR was significant at the 2 mg dose, but 
it showed only a trend at the 4 mg dose (p = 0.06). 
VC increased significantly after infusion of prenal­
terol 1 mg or more. 
The plasma level of metoprolol one hour after in­
gestion of the tablet was 285 ±123 nmol/l. The plas­
ma levels of terbutaline and prenalterol at the end of 
the study were 70 ± 7 nmol/l and 132 ± 4 nmol/l, re­
spectively. No correlation was found between the 
changes in ventilatory and haemodynamic indices 
and the plasma levels of the various drugs. 
Discussion 
Asthmatic patients with an increase of at least 20% in 
FEV, after maximal stimulation with a betaj-agonist 
were accepted for the study, to ensure that the bron­
chodilatation was mediated via beta-receptors in the 
airways. To reduce baseline variation in lung func­
tion and to avoid the morning dip of ventilation in 
asthmatics, all measurements were performed in the 
afternoon (Connolly 1979; Greefhorst and Van Her­
waarden 1981). 
Terbutaline infusion caused marked change in 
the haemodynamic indices. It is well-established that 
terbutaline induces vasodilatation via stimulation of 
beta^-receptors in the muscle vessels (Sackner et al. 
1975; Sharma and Goodwin 1978; Theule and Majid 
1980), so the decrease in diastolic BP can be ex­
plained by this vasodilatation. A decrease in MAP, 
however, is counteracted by increased sympathetic 
tone mediated via the baroreceptor reflex, which re­
sulted in an increase in HR and systolic BP. 
Prenalterol infusion caused quite different hae­
modynamic effects. The diastolic BP did not alter, 
suggesting that prenalterol had no dilator effect on 
the vascular beta2-receptors (Carlsson et al. 1977). 
The haemodynamic changes have then to be ex­
plained by direct stimulation of beta preceptors in 
the heart. Prenalterol has a positive inotropic effect 
and causes an increase in ejection fraction, which 
can account for the increase in systolic BP and MAP 
(Ronn et al. 1979). The rise in MAP increases para­
sympathetic tone via the baroreceptor reflex, which, 
in combination with the positive chronotropic effect 
of prenalterol, resulted in no important net increase 
in HR. The haemodynamic changes during infusion 
of prenalterol and terbutaline are compatible, there­
fore, with their betapselective and beta2-selective 
character, respectively. 
Comparing the haemodynamic profiles, it can be 
concluded that the increase in HR during terbutaline 
is explicable by a reflex mechanism, and that it pro­
duced only limited stimulation of cardiac receptors. 
Terbutaline infusion, as expected in asthmatic 
patients, caused considerable bronchodilatation, as 
shown by the increase in the ventilatory indices. 
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Prenalterol caused a small increase in the ventila­
tory indices, which was significant only at the higher 
doses used (Fig. 2). Prenalterol has been identified as 
a non-selective beta-adrenoceptor ligand with partial 
agonistic betai-adrenoceptor activity (Carlsson et al. 
1977; Manders et al. 1980; Hedberg and Mattson 
1981). In view of the non-selective affinity of prenal­
terol for both types of beta-receptors, it may carry 
some risk of increased bronchialobstruction in asth­
matics. Johansson and Waldeck (1980) have shown 
that very high doses of prenalterol exert a blocking 
action on beta2-receptors. In the present patients, 
however, a small improvement in ventilation was 
seen. In studies on isolated guinea pig trachea in vit­
ro prenalterol caused relaxation, which could be 
blocked by the betapselective blocker practolol and 
not by the beta2-selective blocker IPS 339 (Johansson 
and Waldeck 1981). Accordingly, the induced bron­
chodilatation can be attributed to stimulation of be-
tai-receptors in the airways. The increase in ventila­
tion induced by prenalterol was of similar magnitude 
to the decrease induced by metoprolol, which sup­
ports the assumption that both changes are mediated 
via the available betai-receptors. 
On the other hand prenalterol would not be ex­
pected to be as effective as terbutaline in inducing 
bronchodilatation, because in ligand studies the 
number of beta2-receptors in airways has been 
shown to be about five times larger than that of 
betai-receptors (Bamett et al. 1978; Hancock el al. 
1979). 
In addition to these receptor ligand studies, the 
present findings suggest that the betai-receptors 
found in small numbers in the airways may have a 
functional role in asthmatic patients. 
No relation was found between the ventilatory 
and haemodynamic effects of the vanous drugs and 
their plasma levels. A relationship has been demon­
strated, however, between dosage and mode of ap­
plication of terbutaline and its plasma level (Leferink 
1979). As in this study, a correlation between the in­
crease in HR and the dose of terbutaline has also 
been demonstrated (Carlstrom and Westling 1970; 
Larsson and Svedmyr 1977). 
It is a reasonable conclusion that, although the 
currently used beta2-selective agonists were dev­
eloped in view of their apparently limited influence 
on the cardiovascular system, these agents actually 
exert a marked effect on this system, mainly by their 
vasodilator action. The cardiovascular effects of 
betaj-agomsts cannot be avoided by producing more 
selective compounds, but only by administration of 
these beta2-agonists by inhalation, which results in 
low plasma levels of these drugs (Thmnger and 
Svedmyr 1976). 
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SUMMARY 
0-adrenoceptor blockers are frequently used in the treatment of patients 
with cardiovascular diseases. Soon after their introduction it was found 
that ß-blockers can cause severe bronchospasm in susceptible patients, 
generally described as CNSLD patients (CNSLD = chronic non-specific lung 
disease = chronic obstructive lung disease = COLD). The development of 
bronchospasm is explained by blockade of the β,,-receptors in the airways. 
In this context the introduction of cardioselective or β -selective 
blockers seemed of advantage in the treatment of CNSLD patients with 
cardiovascular diseases. However, these β.-selective blockers were 
found also to exert untoward influences (if usually less marked) on 
ventilation in some CNSLD patients. A study of the ventilatory effects 
of β.-selective blockers is the subject of this thesis. 
Chapter I discusses the receptor theory of the adrenergic system and 
the later division of ß-receptors into two subtypes: ß.- and ß.-
receptors. This chapter also describes the development of selective 
ß-agonists and their possible advantages over non-selective agents in 
the treatment of CNSLD patients. Finally the aim of the study described 
in this thesis is formulated. 
Chapter II discusses the CNSLD concept. The term is too general to be 
of use in selecting patients for clinical research with ß-adrenergic 
substances. On the basis of the pathophysiological mechanisms under-
lying CNSLD, a number of essential features of CNSLD are defined. 
Chapter III relates these features to the ß-adrenergic system and 
discusses their value in predicting a patient's response or non-response 
to a ß-blocker. Only CNSLD patients whose ventilation improves in re-
sponse to a ß-receptor-stimulating substance (whose ß-adrenergic system 
therefore plays a role in the balance between bronchodilator and broncho-
constrictor forces) prove to respond to a ß-blocker. 
Chapter IV describes a comparative study of the three β.-selective 
blockers now available for medical practice (atenolol, metoprolol and 
acebutolol) in asthmatic patients. Before and after oral administration 
53 
of the ß-blockers, ventilation was measured before, during and after 
exercise. Subsequently ventilation was measured after a stimulation test 
with inhaled terbutaline. The ß-blockers all caused diminution of 
ventilation, without inter-agent differences in effect. Acebutolol was 
found partly to block the bronchodilator effect of inhaled terbutaline, 
which might indicate lower β.-selectivity. The ß-blockers proved to 
exert no influence on bronchodilation during exercise, nor on exercise-
induced bronchospasm. This part of the study was published in the European 
Journal of Clinical Pharmacology 1981, 20: 417-421. The findings prompted 
an expansion of the study in two directions. 
Chapter V describes measurements of the ventilatory and haemodynamic 
effects of increasing intravenous doses of terbutaline during meto-
prolol or acebutolol medication in asthmatic patients. Again it was 
found that acebutolol blocked the bronchodilator effect of terbutaline 
significantly more than metoprolol, showing that acebutolol is in fact 
less β.-selective than metoprolol. A negative correlation was found 
between the plasma levels of acebutolol and its active metabolite on 
the one hand, and the degree of blockade of the bronchodilator effect 
of terbutaline on the other. This part of the study was published in 
the European Journal of Clinical Pharmacology 19Θ2, 23: 203-208. 
Chapter VI considers the question whether the presence of β.-receptors 
in the airways could explain the ventilation-reducmg effect of β.-
selective blockers in asthmatic patients. Also an explanation was sought 
for the cardiac side effects of the ËL-selective receptor stimulator 
terbutaline, which are often ascribed to a direct action on the β-
receptors of the heart. For this purpose asthmatic patients who 
showed diminished ventilation after administration of 100 mg metoprolol, 
where given increasing intravenous doses of terbutaline and prenalterol, 
whereupon haemodynamic and ventilatory parameters were determined. 
Prenalterol is a selective partial β.-agonist which in in vitro 
experiments produced relaxation of tracheal strips - an effect which 
was blocked by a β.-blocker but not by a β.-blocker. The largest doses 
of prenalterol given did indeed improve the ventilation in these 
asthmatic patients; the improvement was of the same order of magnitude 
as the diminution of ventilation during metoprolol administration. It 
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therefore seems reasonable that both effects are caused by stimulation 
or blockade of the B.-receptors in the airways, respectively. 
The tachycardia caused by terbutaline infusion significantly exceeded 
that caused by prenalterol, despite a similar increase in systolic 
blood pressure. This finding warrant the conclusion that the tachy-
cardia observed after terbutaline administration is caused mainly, 
via a reflex mechanism, by the marked terbutaline-induced vasodilation. 
The 3.-selective characteristics of a ß-blocker therefore cannot 
prevent diminution of ventilation in certain patients, although this 
diminution can easily be controlled by administering a β,-receptor 
stimulator. Since the use of β -selective blockers in patients with a 
reversible respiratory obstruction can reduce lung function, it should 
take place under controlled conditions. In such patients, however, 
agents other than ß-blockers should first be considered. 
In the administration of modern ß.-selective receptor stimulators to 
CNSLD patients, the longer duration of action in comparison with non-
selective ß-reeeptor stimulators is more important than the lower 
risk of cardiac side effects, for the latter cannot be prevented 
solely on the basis of their ß--selectivity. The cardiac side effect 
of β -agonists can be reduced, however, by selecting inhalation as 
mode of administration, by which lower plasma levels are achieved. 
This study was published in the European Journal of Clinical Pharma­
cology 1983, 24: 173-178. 
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SAMENVATTING 
ß-adrenoceptor blokkers worden in toenemende mate gebruikt bi] de behan-
deling van patiënten met cardio-vasculaire aandoeningen. Al spoedig na de 
introductie bleken β-blokkers ernstige bronchospasmen te kunnen veroorza­
ken bi] daarvoor gevoelige patiënten, over het algemeen als CARA-patienten 
aangeduid (CARA = chronisch aspecifieke respiratoire aandoeningen = CNSLD 
= chronic non-specific lung disease = COLD = chronic obstructive lung 
disease). Het ontstaan van bronchospasme wordt verklaard door blokkade 
van de 39-receptoren in de luchtwegen. De ontwikkeling van cardio-selec-
tieve of 3.-selectieve blokkers leek in dit opzicht van voordeel te zijn 
bi] de behandeling van CARA-patienten met cardio-vasculaire aandoeningen. 
Deze ß.-selectieve blokkers bleken echter ook, zei het meestal in gerin-
gere mate, nadelige effecten op de ventilatie te hebben bi] sommige CARA-
patienten. Onderzoek naar de ventilatoire effecten van β -selectieve 
blokkers vormt het onderwerp van dit proefschrift. 
Hoofdstuk I gaat in op de receptor-theorie van het adrenerge systeem en 
de latere verfijningen van de ß-receptoren in twee subtypen, β.- en ß.,-· 
Vervolgens wordt de ontwikkeling besproken van selectieve ß-agonisten en 
antagonisten en hun mogelijk voordeel ten opzichte van met-selectieve 
middelen bij gebruik bij CARA-patienten. Tenslotte wordt de doelstelling 
van het onderzoek van dit proefschrift geformuleerd. 
In Hoofdstuk II wordt nader ingegaan op het begrip CARA. Deze term is te 
algemeen om gebruikt te worden voor het selecteren van patiënten voor 
klinische research met B-adrenerge stoffen. Aan de hand van de pathophy-
siologische mechanismen, welke aan CARA ten grondslag liggen, worden een 
aantal wezenlijke kenmerken van CARA geformuleerd. 
In Hoofstuk III wordt de relatie van deze kenmerken met het ß-adrenerge 
systeem en de voorspellende waarde van deze kenmerken ten aanzien van het 
al dan niet reageren van een patient op een β-blokker besproken. Slechts 
CARA-patienten welke een verbetering van hun ventilatie vertonen op een 
ß-receptor stimulerende stof en waarbij het ß-adrenerge systeem dus een 
rol speelt in de balans tussen bronchodilaterende- en bronchoconstric-
toire krachten, blijken te reageren op een ß-blokker. 
In Hoofdstuk IV wordt het vergelijkend onderzoek beschreven van de drie 
momenteel voor gebruik in de praktijk voorhanden zijnde βj-selectieve 
blokkers, atenolol, metoprolol en acebutolol, bij asthmatische patiënten. 
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Voor en na orale toediening van de ß-blokkers werden ventilatiemetingen 
verricht voor, tijdens en na inspanning. Aansluitend werd de ventilatie 
gemeten na een stimulatietest met geïnhaleerd terbutaline. De g-blokkers 
bleken allen geringe, onderling niet verschillende, vermindering van de 
ventilatie te veroorzaken. Acebutolol bleek het bronchodilaterende effect 
van geïnhaleerd terbutaline gedeeltelijk te blokkeren, hetgeen op een 
geringere 0 -selectiviteit zou kunnen duiden. De 3-blokkers bleken geen 
invloed te hebben op de bronchodilatatie tijdens inspanning, noch op 
exercised induced bronchospasme. Dit deel van het onderzoek werd gepubli-
ceerd in het European Journal of Clinical Pharmacology 1981, 20: 417-421. 
Dit onderzoek vormde de aanleiding om het onderzoek in tweeërlei richtin-
gen uit te breiden. 
In Hoofdstuk V werden de ventilatoire en haemodynamische effecten van op-
klimmende doses intraveneus terbutaline gemeten tijdens toediening van 
metoprolol of acebutolol bij asthmatische patiënten. Ook nu bleek acebu-
tolol het bronchodilaterende effect van terbutaline significant meer te 
blokkeren dan metoprolol, zodat acebutolol inderdaad minder β,-selectief 
blijkt te zijn dan metoprolol. Er bleek een negatieve correlatie te be­
staan tussen de hoogte van de plasmaspiegels van acebutolol en zijn ac­
tieve metaboliet en de mate van blokkade van het bronchodilaterende ef­
fect van terbutaline. Dit deel van het onderzoek werd gepubliceerd in het 
European Journal of Clinical Pharmacology 19Θ2, 23: 203-208. 
In Hoofdstuk VI werd de mogelijkheid onderzocht of de aanwezigheid van 
β.-receptoren in de luchtwegen de oorzaak zou kunnen zijn van de venti-
latievermindenng door ßj-selectieve blokkers bij asthmatici. Tevens 
werd gezocht naar een verklaring voor de cardiale bijwerkingen van de 
(^•selectieve receptor stimulator terbutaline, welke vaak wordt toege-
schreven aan een direct effect op de ß-receptoren van het hart. Hiervoor 
werden bij asthmatische patiënten, welke een ventilatie-vermindenng ver-
toonden na toediening van 100 mg metoprolol, opklimmende intraveneuze 
doses terbutaline en prenalterol toegediend, waarna haemodynamische en 
ventilatoire parameters werden vastgelegd. Prenalterol is een selectieve 
partiële β.-agonist welke in in vitro experimenten relaxatie van trachea 
strips vertoonde, welke wel geblokkeerd kon worden door een β -blokker, 
maar niet door een β--blokker. Onder invloed van de hoogste toegediende 
doses prenalterol bleek inderdaad een ventilatie-verbetenng bij deze 
asthmatische patiënten gevonden te worden, welke van de zelfde orde van 
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grootte was als de ventilatie-verminclering ti]dens metoprolol-toediening. 
Het li]kt dus aannemelijk dat beide effecten veroorzaakt worden door 
respectievelijk stimulatie of blokkade van de β.-receptoren in de lucht­
wegen. 
De tachycardieën veroorzaakt door terbutaline-infusie waren aanzienlijk 
groter dan die veroorzaakt door prenalterol ondanks een gelijke stijging 
van de systolische bloeddruk. Op grond hiervan kan geconcludeerd worden 
dat de tachycardieën na toediening van terbutaline voornamelijk reflex-
matig door de sterke, door terbutaline geïnduceerde vasodilatatie, ver-
oorzaakt worden. 
Het ¡3. -selectieve karakter van een ß-blokker zal dus m e t kunnen voor-
komen dat bij bepaalde patiënten een vermindering van de ventilatie op-
treedt, alhoewel zo'n vermindering zeer makkelijk op te heffen zal zijn 
door toediening van een ß_-receptor stimulator. Het gebruik van β -
selectieve blokkers bij patiënten met een reversibele luchtwegobstructie 
kan dus een vermindering van de longfunctie geven. Hierdoor zal het ge-
bruik van deze middelen bij deze patiënten onder gecontroleerde omstan-
digheden dienen plaats te vinden. Men dient dan ook eerst andere midde-
len dan ß-blokkers bij dergelijke patiënten te overwegen. 
Bij de toediening van de moderne β -selectieve receptor stimuleerders 
aan CARA-patienten is de langere werkingsduur ten opzichte van de niet-
selectieve ß-receptor stimuleerders van meer belang dan de mindere 
cardiale bijwerkingen, daar op grond van hun ß.-selectiviteit alleen, 
cardiale bijwerkingen niet kunnen worden voorkomen. Vermindering van 
de cardiale bijwerkingen van ß^-agomsten kan wel verkregen worden door 
middel van toediening per inhalatie, waarbij lagere plasmaspiegels wor-
den bereikt. Dit onderzoek werd gepubliceerd in het European Journal of 
Clinical Pharmacology 1983, 24: 173-178. 
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met veel hulp van de bibliothecaris van de Medische Faculteit, de heer 
E. de Graaff, en zijn medewerkers verkregen. 
De analyses van serum-monsters werden verricht door Astra Pharmaceuticals 
Nederland en Rhône-Poulenc Nederland. 
De tekeningen werden met veel accuratesse vervaardigd door de tekenafde-
ling van de Medische Faculteit te Nijmegen en de heer J.C. Dalman van 
het Medisch Centrum Dekkerswald. 
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1. Het produceren van nog selectievere β -adrenoceptor antagonisten dan 
de momenteel beschikbare, m de verwachting dat de invloed op de 
luchtwegen daardoor minder wordt, is niet zinvol. 
2. Het produceren van nog selectievere β -adrenoceptor agonisten dan de 
momenteel beschikbare, in de verwachting dat de invloed op het hart 
daardoor minder wordt, is niet zinvol. 
3. De door inspanning veroorzaakte bronchusobstructie wordt niet beïn-
vloed door β -selectieve adrenoceptor blockade. 
4. Het voordeel van de moderne β -adrenoceptor agonisten ten opzichte 
van de oudere, niet selectieve ß-adrenoceptor agonisten is meer ge-
legen in het feit dat de werkingsduur toenam dan dat de bijwerkingen 
afnamen. 
5. Het bewijs van een klinisch relevante vorm van desensitisatie bij 
gebruik van ß-adrenoceptor agonisten is tot nu toe niet geleverd 
(Tashkin e.a.. Am Rev Respir Dis 1982, 125: 185-193). 
6. Publicatie van klinisch pharmacologisch onderzoek bij patiënten, 
aangeduid als lijdende aan CARA zonder duidelijke nadere karakte-
nsatie dient vermeden te worden. 
7. ledere CARA-patient heeft tenminsten éénmaal in zijn leven recht op 
onderzoek door een longarts ter inventarisatie en karaktensatie van 
zijn CARA. 
8. Bij een gedecompenseerde, dyspnoeische, shockenge patient dient de 
mogelijkheid van het bestaan van Beri-beri overwogen te worden 
(eigen waarneming). 
9. Het vaststellen van een norm-praktijk van een specialist, uitgaande 
van een 50 à 60-urige werkweek gaat voorbij aan de maatschappelijke 
verworvenheden van deze tijd en belemmert de instroom van jonge(re) 
specialisten. 
10. Het niet mogen missen van een diagnose werkt in de gezondheidszorg 
sterk kostenverhogend. 
11. De kwalificatie "top-ziekenhuis", welke in deze tijd gebezigd wordt, 
kan niet geclaimd worden op grond van getalsmatige verhoudingen, 
doch slechts op grond van prestaties. 
12. Iemands aandacht en energie naar de buitenwereld is zelden in even-
wicht met de naar binnen gerichte aandacht en energie. 
13. Een te sterke koppeling tussen ethiek en portemonnaie dient bij een 
werker in de gezondheidszorg onmogelijk gemaakt te worden. 
A.P.M. Greefhorst 
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